Source: Design+Industry
ADVANCELL
Advancing therapies for the treatment of cancer:
NSW Health Medical Devices Fund’s boost towards AdvanCell research & development
The study of cancer has occupied medical researchers for centuries. Countless universities, organisations, and individuals have dedicated their resources and lives to the battle to conquer cancer. Over the years, many different methods have been attempted to treat, and sometimes to cure cancer.
Australian radiopharmaceutical company, AdvanCell Isotopes are one of three companies backed in 2021 by the NSW Health Medical Devices Fund.
AdvanCell received a $2.1 million grant for the continued development of their innovative isotope generator. The generator will produce clinical doses of a high-value radionuclide known as 212Pb, or as AdvanCell calls it, Alpha-212.
As an isotope of 212Pb decays, a single alpha particle (a helium nuclei) is emitted. Pairing the isotope with cancer cell targeting molecules results in a radiopharmaceutical to target, and eradicate, specific cancer cells – a revolutionary cancer treatment called “Targeted Alpha Therapy”.
